Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.

ABSTRACT:

Background

Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for documented IPF, with similar reimbursement criteria with respect to disease characteristics, prescription through a dedicated form, and IPF diagnosis established in multidisciplinary discussion.

Research question

The data of the comprehensive French National Health System were used to evaluate outcomes in patients newly treated with pirfenidone or nintedanib in 2015-2016.

Study design and methods

Patients aged < 50 years or who had pulmonary fibrosis secondary to an identified cause were excluded. All-cause mortality, acute respiratory-related hospitalisations and treatment discontinuation

SUBMITTER: Belhassen M 

PROVIDER: S-EPMC8094468 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature